PRL-3 AS A BIOMARKER FOR THE PROGNOSIS OF CANCER AND A TARGET FOR THERAPY
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
May 25, 2017
app pub date -
Feb 7, 2014
filing date -
Feb 7, 2014
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Previously, we have shown that a cancer associated-PRL-3 intracellular phosphatase is a potential therapeutic target for PRL-3 antibody therapy. PRL-3 has recently emerged as a potentially useful biomarker for cancer prognosis, particularly the prediction of cancer metastasis (Matsukawa et al, 2010, Ren et al, 12 2009). Here we demonstrate that PRL-3 can act as an independent prognostic marker for cancers.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully